Maze Therapeutics (NASDAQ:MAZE) Receives Buy Rating from BTIG Research

BTIG Research reiterated their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $46.00 price target on the stock.

A number of other equities analysts also recently weighed in on MAZE. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective for the company. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Finally, Guggenheim raised their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $64.11.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $31.73 on Wednesday. The firm has a market cap of $1.53 billion, a P/E ratio of -1.52 and a beta of 4.47. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $53.65. The firm’s 50 day moving average price is $45.98 and its two-hundred day moving average price is $37.55.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter.

Insider Buying and Selling at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 10,000 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. The trade was a 43.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 245,000 shares of company stock valued at $10,504,792 in the last ninety days.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ensign Peak Advisors Inc acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $227,000. Frazier Life Sciences Management L.P. raised its position in shares of Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after buying an additional 438,274 shares in the last quarter. Washington University bought a new stake in shares of Maze Therapeutics in the third quarter valued at approximately $5,463,000. ArrowMark Colorado Holdings LLC acquired a new stake in Maze Therapeutics during the third quarter worth approximately $14,135,000. Finally, Virtus Investment Advisers LLC acquired a new stake in Maze Therapeutics during the second quarter worth approximately $85,000.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Topline Phase 2 HORIZON results showed meaningful proteinuria (uACR) reductions across a broad APOL1‑mediated kidney disease population, including a 61.8% mean uACR reduction in an FSGS subgroup and large reductions in non‑diabetic patients; company plans to advance MZE829 into a pivotal program. Globe Newswire: Positive Topline Data
• Positive Sentiment: Analysts reacted bullishly despite volatility — HC Wainwright raised its price target sharply (to $110) and BTIG reaffirmed a Buy with a $46 target, supporting upside expectations if pivotal data confirm benefit. Benzinga: Analyst Coverage
• Neutral Sentiment: Maze reported Q4 and full‑year 2025 results (EPS -$0.65) and highlighted a strong cash position (about $360M) with runway into 2028 — gives the company financial flexibility to fund pivotal development. Earnings Release
• Neutral Sentiment: Board strengthening: Neil Kumar (BridgeBio founder/CEO) was added to the board, which could add industry experience and credibility around development strategy. TipRanks: Board Addition
• Negative Sentiment: Despite positive data, the stock plunged and the company “lost nearly a third” of market value in heavy trading as some investors viewed the readout as mixed or chose to take profits, driving sharp intraday declines. BioSpace: Market Reaction
• Negative Sentiment: Insider sale: an executive exercised options and sold 15,000 shares (~$736K), an action that may have increased sell‑side pressure and contributed to the stock drop. Motley Fool: Insider Sale
• Negative Sentiment: Mixed media/analyst headlines amplified volatility — some outlets emphasize “best‑in‑class potential” while others focus on the sell‑off, increasing short‑term uncertainty and trading volume. FierceBiotech: Mixed Coverage

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.